Early improvement in carotid plaque Echogenicity by Acarbose in patients with acute coronary syndromes

Circulation Journal

Volumn 76, Issue 6, 2012, Pages 1452-1460

  Hirano, Mitsumasa ^a   Nakamura, Takamitsu ^a   Obata, Jyun ei ^a   Fujioka, Daisuke ^a   Saito, Yukio ^a   Kawabata, Ken ichi ^a   Watanabe, Kazuhiro ^a   Watanabe, Yosuke ^a   Kugiyama, Kiyotaka ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

C reactive protein; Carotid arteries; Plaque vulnerability; Type 2 diabetes mellitus; Ultrasound

Indexed keywords

ACARBOSE; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; PRAVASTATIN; ROSUVASTATIN; SULFONYLUREA; THIENOPYRIDINE DERIVATIVE; TRIACYLGLYCEROL;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; ATHEROMA; CAROTID ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS;

ACARBOSE; ACUTE CORONARY SYNDROME; ADULT; AGED; ALPHA-GLUCOSIDASES; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; DIABETES MELLITUS, TYPE 2; ENZYME INHIBITORS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; JAPAN; MALE; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC; PREDICTIVE VALUE OF TESTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84861625843     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-1524     Document Type: Article

References (40)

1. Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyper glycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: A systematic overview. Lancet 2000; 355: 773-778.
2. Stranders I, Diamant M, van Gelder RE, Spruijt HJ, Twisk JW, Heine RJ, et al. Admission blood glucose level as risk indicator of death after myocardial infarction in patients with and without diabetes mellitus. Arch Intern Med 2004; 164: 982-988.
3. Wong VW, Ross DL, Park K, Boyages SC, Cheung NW. Hyperglycemia: Still an important predictor of adverse outcomes following AMI in the reperfusion era. Diabetes Res Clin Pract 2004; 64: 85-91.
4. Zarich SW, Nesto RW. Implications and treatment of acute hyperglycemia in the setting of acute myocardial infarction. Circulation 2007; 115: e436-e439.
5. Ceriello A, Zarich SW, Testa R. Lowering glucose to prevent adverse cardiovascular outcomes in a critical care setting. J Am Coll Cardiol 2009; 53(Suppl): S9-S13.
6. Marfella R, Siniscalchi M, Esposito K, Sellitto A, De Fanis U, Romano C, et al. Effects of stress hyperglycemia on acute myocardial infarction: Role of inflammatory immune process in functional cardiac outcome. Diabetes Care 2003; 26: 3129-3135.
7. Malmberg K. Prospective ran domised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997; 314: 1512-1515.
8. Goyal A, Mahaffey KW, Garg J, Nicolau JC, Hochman JS, Weaver WD, et al. Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: Results from the CARDINAL study. Eur Heart J 2006; 27: 1289-1297.
9. Kosiborod M, Inzucchi SE, Krumholz HM, Masoudi FA, Goyal A, Xiao L, et al. Glucose normalization and outcomes in patients with acute myocardial infarction. Arch Intern Med 2009; 169: 438-446.
10. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes, Circulation 2001; 104: 365-372.
11. Goldstein JA, Demetriou D, Grines CL, Pica M, Shoukfeh M, O'Neill WW. Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med 2000; 343: 915-922.
12. Rothwell PM, Villagra R, Gibson R, Donders RC, Warlow CP. Evidence of a chronic systemic cause of instability of atherosclerotic plaques. Lancet 2000; 355: 19-24.
13. Hirano M, Nakamura T, Kitta Y, Yano T, Kobayashi T, Sano K, et al. Rapid improvement of carotid plaque echo genicity within 1 month of pioglitazone treatment in patients with acute coronary syndrome. Atherosclerosis 2009; 203: 483-488.
14. Nakamura T, Obata JE, Kitta Y, Takano H, Kobayashi T, Fujioka D, et al. Rapid stabilization of vulnerable carotid plaque within 1 month of pitavastatin treatment in patients with acute coronary syndrome. J Cardiovasc Pharmacol 2008; 51: 365-371.
15. Watanabe K, Sugiyama S, Kugiyama K, Honda O, Fukushima H, Koga H, et al. Stabilization of carotid at hero ma assessed by quantitative ultrasound analysis in non hyper cholesterolemic patients with coronary artery disease. J Am Coll Cardiol 2005; 46: 2022-2030.
16. Takiuchi S, Rakugi H, Honda K, Masuyama T, Hirata N, Ito H, et al. Quantitative ultrasonic tissue characterization can identify high-risk atherosclerotic alteration in human carotid arteries. Circulation 2000; 102: 766-770.
17. Waki H, Masuyama T, Mori H, Maeda T, Kitade K, Moriyasu K, et al. Ultrasonic tissue characterization of the atherosclerotic carotid artery: Histological correlates or carotid integrated backscatter. Circ J 2003; 67: 1013-1016.
18. Grønholdt ML, Nordestgaard BG, Bentzon J, Wiebe BM, Zhou J, Falk E, et al. Macrophages are associated with lipid-rich carotid artery plaques, echolucency on B-mode imaging, and elevated plasma lipid levels. J Vasc Surg 2002; 35: 137-145.
19. Shepard RK, Miller JG, Wickline SA. Quantification of atherosclerotic plaque composition in cholesterol-fed rabbits with 50-MHz acoustic microscopy. Arterioscler Thromb 1992; 12: 1227-1234.
20. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NIDDM trial. JAMA 2003; 290: 486-494.
21. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: Meta-analysis of seven long-term studies. Eur Heart J 2004; 25: 10-16.
22. Ceriello A, Taboga C, Tonutti L, Giacomello R, Stel L, Motz E, et al. Post-meal coagulation activation in diabetes mellitus: The effect of acarbose. Diabetologia 1996; 39: 469-473.
23. Hanefeld M. Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes. Cardiovasc Diabetol 2007; 6: 20.
24. Kosiborod M, Deedwania P. An overview of glycemic control in the coronary care unit with recommendations for clinical management. J Diabetes Sci Technol 2009; 3: 1342-1351.
25. DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: Comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397-405.
26. Baron AD. Postprandial hyper glycaemia and alpha-glucosidase inhibitors. Diabetes Res Clin Pract 1998; 40(Suppl): S51-S55.
27. Nguyen-Thanh HT, Benzaquen BS. Screening for subclinical coronary artery disease measuring carotid intima media thickness. Am J Cardiol 2009; 104: 1383-1388.
28. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26: S5-S20.
29. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: A report of the Am College of Cardiology/Am Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction). Circulation 2007; 116: e148-e304.
30. Kim MK, Suk JH, Kwon MJ, Chung HS, Yoon CS, Jun HJ, et al. Nateglinide and acarbose for postprandial glucose control after optimizing fasting glucose with insulin glargine in patients with type 2 diabetes. Diabetes Res Clin Pract 2011; 92: 322-328.
31. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM. C-reactive protein is more strongly related to post-glucose load glucose than to fasting glucose in non-diabetic subjects: The Insulin Resistance Atherosclerosis Study. Diabet Med 2002; 19: 939-943.
32. Cardellini M, Andreozzi F, Laratta E, Marini MA, Lauro R, Hribal ML, et al. Plasma interleukin-6 levels are increased in subjects with impaired glucose tolerance but not in those with impaired fasting glucose in a cohort of Italian Caucasians. Diabetes Metab Res Rev 2007; 23: 141-145.
33. Kawano H, Motoyama T, Hirashima O, Hirai N, Miyao Y, Sakamoto T, et al. Hyperglycemia rapidly suppresses flow-mediated endothelium- dependent vasodilation of brachial artery. J Am Coll Cardiol 1999; 34: 146-154.
34. Qualmann C, Nauck MA, Holst JJ, Orskov C, Creutzfeldt W. Glucagon- like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut: A study using alpha-glucosidase inhibition (acarbose). Scand J Gastroenterol 1995; 30: 892-896.
35. Chilton R, Wyatt J, Nandish S, Oliveros R, Lujan M. Cardiovascular comor bidities of type 2 diabetes mellitus: Defining the potential of glucagonlike peptide-1-based therapies. Am J Med 2011; 124(Suppl): S35-S53.
36. Nissen SE, Gurley JC, Grines CL, Booth DC, McClure R, Berk M, et al. Intravascular ultrasound assessment of lumen size and wall morphology in normal subjects and patients with coronary artery disease. Circulation 1991; 84: 1087-1099.
37. Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova- Kurktschiev T. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 2004; 35: 1073-1078.
38. Solberg LA, Eggen DA. Localization and sequence of development of atherosclerotic lesions in the carotid and vertebral arteries. Circulation 1971; 43: 711-724.
39. Ambrose JA, Martinez EE. A new paradigm for plaque stabilization. Circulation 2002; 105: 2000-2004.
40. Sano K, Nakamura T, Hirano M, Kitta Y, Kobayashi T, Fujioka D, et al. Comparative study of bezafibrate and pravastatin in patients with coronary artery disease and high levels of remnant lipoprotein. Circ J 2010; 74: 1644-1650.